Life Tech Genetic Analysis Revenues Decline as qPCR Royalties Wither, Though QuantStudio Sales Spike | GenomeWeb

Life Technologies this week reported a 6 percent drop in second-quarter revenues for its Genetic Analysis segment, primarily due to dwindling qPCR royalties and a decline in sales of its SOLiD sequencers.

However, excluding these "headwinds," Genetic Analysis revenues increased 5 percent, the company said, driven in part by sales of its Ion Torrent sequencers and "a record number" of its QuantStudio 12K Flex real-time and digital PCR platform.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.